Development↦Protocol↦Study Participants↦Participant Risks and Benefits
What is it? Why is it important?
When participating in a study or research project, study / project participants have both risks and benefits.
Risks may include that:
- The new study treatment may cause serious side effects, does not work as intended or is not better than a standard treatment
- A participant is part of the placebo group and thus not part of the treatment group
- Medical appointments become too cumbersome or time consuming causing unwanted disruptions in daily life
Benefits may include that participants:
- Get access to novel treatments not yet available to the general public
- Become more closely monitored with more frequent health check-ups
- Can play a more active role in their health care
In any case, the risk-benefit ratio of the study must be favourable with participant safety taking precedence over research interest (i.e. principles of ethics)
More
In studies, participants also have responsibilities. When signing the Informed Consent Form (ICF), participants agree to comply with study instructions.
Not complying with study instruction can carry risks, such as when participants:
What do I need to do?
As a SP-INV and Site-INV, define any risks and burdens participants may be subjected to in your study.
Ensure study risks:
- Are documented in the Participant Information Sheet (PIS) in such a manner for a lay person to understand its implications
- Are explained to participants, and processes are in place that ensure that questions are answered to the participant`s satisfaction
Participants must understand any study risks before signing the Informed Consent Form (ICF). In the event of:
- Communication problems (e.g. language), plan for an independent qualified translator to be consulted
- Physical or cognitive problems, plan for information and consent to be provided in a non-written form, with a written confirmation from a witness confirming adherence to the informed consent process
During the informed consent process, benefits to study participants can be discussed. However, in order to guarantee participant safety, informing about potential study risks should be the focus.
Where can I get help?
Your local CTU↧ can support you with experienced staff regarding this topic
Basel, Departement Klinische Forschung, CTU, dkf.unibas.ch
Lugano, Clinical Trials Unit, CTU-EOC, www.ctueoc.ch
Bern, Clinical Trials Unit, CTU, www.ctu.unibe.ch
Geneva, Clinical Research Center, CRC, crc.hug.ch
Lausanne, Clinical Research Center, CRC, www.chuv.ch
St. Gallen, Clinical Trials Unit, CTU, www.kssg.ch
Zürich, Clinical Trials Center, CTC, www.usz.ch
References
The Federal Act on Data Protection
Declaration of Helsinki – see in particular
- 4, 7-9, 14 General principles
- 16 – 18 Risks, burdens and benefits
ICH GCP E6(R2) – see in particular guidelines
- 4.8 Informed Consent
- 5.16 Safety Information
Swiss Law
HRA – see in particular articles
- Art. 8 Right to receive information
- Art. 15 Safety and protective measures
- Art. 16 Informed Consent
ClinO – see in particular articles
- Art. 5 Rules of Good Clinical Practice
- Art. 7 Information
- Art. 8 Exception to written form
- Art. 9 Consequences of revocation to consent
- Art. 19, 20, 49, and 61 Risk Categorisation
ClinO-MD – see in particular article
- Art. 6 Risk categorisation of clinical investigations
HRO – see in particular article
- Art. 7 Risk categorisation